Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16199
Title: Australian Group on Antimicrobial Resistance Australian Enterococcal Sepsis Outcome Programme annual report, 2014
Austin Authors: Coombs, Geoffrey W;Daley, Denise A;Thin Lee, Yung;Pang, Stanley;Pearson, Julie C;Robinson, J Owen;Johnson, Paul D R ;Kotsanas, Despina;Bell, Jan M;Turnidge, John D
Institutional Author: Australian Group on Antimicrobial Resistance
Affiliation: Austin Health, Heidelberg, Victoria, Australia
Australian Collaborating Centre for Enterococcus and Staphylococcus Species (ACCESS) Typing and Research, School of Veterinary and Life Sciences, Murdoch University, Murdoch, Western Australia, Australia
Department of Microbiology and Infectious Diseases, PathWest Laboratory Medicine-WA, Fiona Stanley Hospital, Murdoch, Western Australia, Australia
Australian Group on Antimicrobial Resistance, Fiona Stanley Hospital, Murdoch, Western Australia, Australia
Microbiology and Infectious Diseases Departments, Austin Health, Heidelberg, Victoria, Australia
Infectious Diseases, Monash Health, Monash Medical Centre, Clayton, Victoria, Australia
SA Pathology, Department of Microbiology and Infectious Diseases, Women's and Children's Hospital, North Adelaide, South Australia, Australia
al Sciences, UniverDepartments of Pathology, Paediatrics and Molecular and Biomedicsity of Adelaide, Adelaide, South Australia, Australia
Issue Date: Jun-2016
metadata.dc.date: 2016-06
Publication information: Communicable Diseases Intelligence 2016; 40 (2): E236-243
Abstract: From 1 January to 31 December 2014, 27 institutions around Australia participated in the Australian Enterococcal Sepsis Outcome Programme (AESOP). The aim of AESOP 2014 was to determine the proportion of enterococcal bacteraemia isolates in Australia that were antimicrobial resistant, and to characterise the molecular epidemiology of the Enterococcus faecium isolates. Of the 952 unique episodes of bacteraemia investigated, 94.4% were caused by either E. faecalis (54.9%) or E. faecium (39.9%). Ampicillin resistance was detected in 0.6% of E. faecalis and in 89.4% of E. faecium. Vancomycin non-susceptibility was reported in 0.2% and 46.1% of E. faecalis and E. faecium respectively. Overall 51.1% of E. faecium harboured vanA or vanB genes. For the vanA/B positive E. faecium isolates, 81.5% harboured vanB genes and 18.5% vanA genes. The percentage of E. faecium bacteraemia isolates resistant to vancomycin in Australia is significantly higher than that seen in most European countries. E. faecium consisted of 113 pulsed-field gel electrophoresis pulsotypes of which 68.9% of isolates were classified into 14 major pulsotypes containing 5 or more isolates. Multilocus sequence typing grouped the 14 major pulsotypes into clonal cluster 17, a major hospital-adapted polyclonal E. faecium cluster. The geographical distribution of the 4 predominant sequence types (ST203, ST796, ST555 and ST17) varied with only ST203 identified across most regions of Australia. Overall 74.7% of isolates belonging to the four predominant STs harboured vanA or vanB genes. In conclusion, the AESOP 2014 has shown enterococcal bacteraemias in Australia are frequently caused by polyclonal ampicillin-resistant high-level gentamicin resistant vanA or vanB E. faecium, which have limited treatment options.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16199
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/27522135
Type: Journal Article
Subjects: Drug Resistance, Microbial
Enterococcus faecium
Vancomycin-Resistant Enterococci
Appears in Collections:Journal articles

Files in This Item:
File Description SizeFormat 
cdi4002h.pdf440.14 kBAdobe PDFThumbnail
View/Open
Show full item record

Page view(s)

20
checked on Nov 29, 2022

Download(s)

44
checked on Nov 29, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.